---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013788"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:08:35.101575+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical reports FY2025 net income $5.0M vs loss $16.5M; revenue $134M (+14% YoY)

## Summary
- Full-year 2025 revenue $134.0M (+14% YoY); net income $5.0M ($0.03 diluted EPS) vs net loss $16.5M in 2024.
- Q4 2025 revenue $32.4M (+3% YoY); net income $0.1M vs net loss $3.2M; non-GAAP adjusted EBITDA $1.9M vs $0.4M.
- Completed sale of non-core Coflex/CoFix assets and international hardware to Companion Spine for $21.4M cash.
- Launched nanOss Strata synthetic bone graft and CollagenX bovine collagen product; total cash $17.3M at Dec 2025 + $10.5M received Feb 2026.
- FY2026 revenue guidance $95M-$99M reflecting divestiture impact and cessation of license revenue; expects free cash flow positive.

## SEC filing metadata
- accession: 0001493152-26-013788
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/0001493152-26-013788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013788
- JSON: https://secwatch.observer/filing/0001493152-26-013788.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013788.txt

## Key facts
- Earnings Releases
  Xtant Medical Holdings, Inc. reported Fourth Quarter 2025 results: revenue $32.4 million, net income $0.1 million.
  - Period: Fourth Quarter 2025
  - Revenue: $32.4 million
  - Net income: $0.1 million
  - Result: reported results
  source text: Fourth quarter 2025 revenue grew 3% to $32.4 million, compared to $31.5 million for the same period in 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/0001493152-26-013788-index.htm
- Earnings Releases
  Xtant Medical Holdings, Inc. reported Full Year 2025 results: revenue $134.0 million, net income $5.0 million, EPS $0.03 per diluted share.
  - Period: Full Year 2025
  - Revenue: $134.0 million
  - Net income: $5.0 million
  - EPS: $0.03 per diluted share
  - Result: reported results
  source text: and may be different from non-GAAP finan --- EX-99.1 (EX-99.1) --- Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 31, 2025 with an
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/0001493152-26-013788-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.